GI Dynamics launches a U.S. trial of its EndoBarrier diabetes device, aiming to use the data to back a pre-market approval application with the FDA.
GI Dynamics (ASX:GID) said today that it's launched a U.S. pivotal trial of its EndoBarrier anti-diabetes weight loss device, hoping to use the study data to back a pre-market approval application with the FDA.
President & CEO Stu Randle told MassDevice.com that the Lexington, Mass.-based company hopes to put a PMA application before the federal watchdog agency "in late 2015."
The EndoBarrier is a plastic sleeve designed to line the gut and prevent the absorption of food. The U.S. trial will span 25 U.S. sites, enrolling up to 500 obese patients with uncontrolled Type II diabetes and assessing changes over a period of 12 months.
Randle told us that the differentiator for GI Dynamics with this trial is that its primary endpoint is reduction in blood sugar, not weight loss (which is a seconday endpoint, he said).
"The data we used overseas gave [the FDA] confidence that we're going right to a pivotal trial," Randle said.
Earlier studies demonstrated that the EndoBarrier helps control blood sugar levels and induce weight loss of up to 20% in a year. The device won CE Mark approval in the European Union in 2010 and hit the market in Australia the next year.
Here's a look at some of the top funding stories for medical device companies this week.
FDA officials warn against the use of "laparoscopic power morcellation" for the removal of uterine...
Bio-artificial liver maker Vital Therapies takes its IPO even lower, now planning to open at $12 per...
California surgical devices maker Cardica details a public offering of common and preferred stock...